Neurocrine Biosciences, Inc.
MX ˙ BMV ˙ US64125C1099
SecurityMX:NBIX / Neurocrine Biosciences, Inc.
InstitutionCI Private Wealth, LLC
Latest Disclosed Ownership45,035 shares
Latest Disclosed Value $ 5,911,518
CI Private Wealth, LLC reports 740.68% increase in ownership of NBIX / Neurocrine Biosciences, Inc.

On May 15, 2026 - CI Private Wealth, LLC filed a 13F-HR form disclosing ownership of 45,035 shares of Neurocrine Biosciences, Inc. (MX:NBIX) valued at $5,911,518 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on March 9, 2026 disclosing 5,357 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of 740.68% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 45,035 39,678 740.68 5,912 678.79 0.0085
2026-03-09 2025-12-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 5,357 1,352 33.76 760 35.05 0.0010
2026-02-19 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 7,292 3,287 1,034 0.0004
2025-11-14 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,005 -866 -17.78 562 -8.17 0.0009
2025-09-26 2025-06-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 4,871 671 15.98 612 31.90 0.0008
2025-08-15 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,871 671 612 0.0005
2025-05-14 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,200 -3,727 -47.02 465 -57.12 0.0008
2025-02-10 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 7,927 3,094 64.02 1,082 94.60 0.0018
2024-11-12 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,833 397 8.95 557 -8.85 0.0009
2024-08-13 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 4,436 617 16.16 611 15.97 0.0011
2024-05-09 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,819 637 20.02 527 25.54 0.0009
2024-02-09 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,182 23 0.73 419 18.03 0.0008
2023-11-03 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,159 110 3.61 355 23.69 0.0008
2023-08-10 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 3,049 -2,145 -41.30 288 -45.33 0.0007
2023-05-15 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 5,194 5,194 526 0.0014
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.